Clinical-stage biotechnology company Lipella Pharmaceuticals Inc (Nasdaq:LIPO) on Tuesday announced the receipt of a US patent for its proprietary liposomal drug delivery platform.

The new patent covers key innovations in the company's technology for delivering therapeutic agents via liposome-based vehicles.

This breakthrough technology enables precise, targeted delivery, improving the safety and efficacy of treatments across various therapeutic areas, including oncology, cancer survivorship and immunotherapy. The patent extends market exclusivity for Lipella's lead clinical assets, LP-10 and LP-310, which are currently in Phase 2 trials.

LP-10 is a liposomal formulation of tacrolimus designed to treat haemorrhagic cystitis, while LP-310 is an oral rinse formulation for treating oral lichen planus. Both assets have shown promising results in clinical trials and offer potential solutions for these unmet medical needs.